Lilly fails to persuade Medicare to pay for Alzheimer's imaging drug
September 30, 2013
By Tracy Staton
"The Centers for Medicare & Medicaid Services has handed down its final decision on Eli Lilly's Alzheimer's imaging agent Amyvid. The final answer, after appeals from Lilly and patient groups? No. Medicare won't pay for Amyvid-aided brain scans, not outside of clinical trials."